Medications for Uca1 Rna Human
6 results
Balversa (erdafitinib)
(Erdafitinib)Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations, after disease progression on at least one prior systemic therapy. Use an FDA-approved companion diagnostic for patient selection. It's not recommended for those eligible for prior PD-1 or PD-L1 inhibitor therapy.
Bavencio (avelumab)
(avelumab)EMD Serono, Inc.
Usage: BAVENCIO (avelumab) is indicated for adults and patients aged 12 and older with metastatic Merkel cell carcinoma. It also treats locally advanced or metastatic urothelial carcinoma, both as first-line maintenance after chemotherapy and for previously-treated cases, and is used in combination with axitinib for advanced renal cell carcinoma.
Keytruda (pembrolizumab)
(pembrolizumab)Merck Sharp & Dohme LLC
Usage: KEYTRUDA® is indicated for treating various cancers, including melanoma, non-small cell lung cancer, malignant pleural mesothelioma, head and neck squamous cell cancer, classical Hodgkin lymphoma, and possible others, in both adults and children, depending on specific tumor characteristics and treatment history.
Opdivo (nivolumab)
(nivolumab)E.R. Squibb & Sons, L.L.C.
Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, advanced renal cell carcinoma (RCC), classical Hodgkin lymphoma, and more, in both adults and pediatric patients. It can be used alone or in combination therapies.
Padcev (enfortumab vedotin)
(ENFORTUMAB VEDOTIN)SEAGEN INC.
Usage: PADCEV® is indicated for adult patients with locally advanced or metastatic urothelial cancer. It can be used in combination with pembrolizumab or as a single agent for patients who have received prior PD-1 or PD-L1 inhibitors and platinum chemotherapy, or who are ineligible for cisplatin-based therapy.
Trodelvy (sacituzumab govitecan)
(SACITUZUMAB GOVITECAN)Gilead Sciences
Usage: TRODELVY is indicated for adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received prior treatments, and for those with HR-positive, HER2-negative breast cancer after specific therapies. It also treats adults with locally advanced or metastatic urothelial cancer following platinum chemotherapy and PD-1/PD-L1 inhibition.